Aftorney's Docket No.: 07039-298001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Stephen James Russell et al.

Art Unit : 1632

Serial No.: 09/667,947

Examiner: Shin-Lin Chen

Filed

: September 22, 2000

Title

THERAPEUTIC METHODS AND COMPOSITIONS USING VIRUSES OF THE

RECOMBINANT PARAMYXOVIRIDAE FAMILY

RECEIVED

MAIL STOP SEQUENCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

MAY 2, 8 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

The following correspondence relating to this application is enclosed:

- 1. Response to Notice to Comply (2 pages);
- Copy of Notice to Comply (10 pages); 2.
- Paper Copy of Substitute Sequence Listing (10 pages); 3.
- Verified Statement Under 37 CFR § 1.821(f); 4.
- Computer Readable Diskette; and 5.
- Post card. 6.

Please apply any charges not covered, or any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Monica McCormick Graham, Ph.D.

Reg. No. 42,600

Fish & Richardson P.C., P.A. 60 South Sixth Street

Suite 3300

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

60142250.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 20, 2003

Wareku

Date of Deposit

Signature

Judith A. Wasilkus

Typed or Printed Name of Person Signing Certificate

AF/1632

Attorney's Docket No.: 07039-298001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant: Stephen James Russell et al.

Art Unit : 1632

Serial No.:

09/667,947

Examiner: Shin-Lin Chen

Filed

: September 22, 2000

Title

: THERAPEUTIC METHODS AND COMPOSITIONS USING VIRUSES OF THE

RECOMBINANT PARAMYXOVIRIDAE FAMILY

MAIL STOP AF

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

MAY 2: 9 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

The following correspondence relating to this application is enclosed:

- 1. Amendment and Response to Office Action mailed February 20, 2003 (8 pages);
- 2. Copy of Peng et al., Nature Medicine article (5 pages);
- 3. Copy of Peng et al., Cancer Research article (7 pages); and
- 4. Post card.

Please apply any charges not covered, or any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 5/20/03

Monica McCormick Graham, Ph.D.

Reg. No. 42,600

Fish & Richardson P.C., P.A. 60 South Sixth Street Suite 3300

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

.60142268.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Judith A. Wasilkus

Typed or Printed Name of Person Signing Certificate

Attorney's Docket No.: 07039-29800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Stephen James Russell et al.

Art Unit : 1632

TECH CENTER 1600/2900

Serial No.: 09/667,947

Examiner: Shin-Lin Chen

Filed

September 22, 2000

Title

: THERAPEUTIC METHODS AND COMPOSITIONS USING VIRUSES OF THE

RECOMBINANT PARAMYXOVIRIDAE FAMILY

MAIL STOP SEQUENCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated February 20, 2003 (copy enclosed), Applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, Applicants submit a substitute Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f). In the substitute sequence listing, the <213> section recites "artificial sequence" in place of "fragment." The substitute specification also provides the information for the <220> and <223> sections. No new matter has been introduced.

Applicants respectfully request entry of the substitute paper copy and computer readable copy of the Sequence Listing filed herewith in the instant application.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	May 20	J. 20
CD :		

Date of Deposit

Signature

Judith A. Wasilkus

Typed or Printed Name of Person Signing Certificate

Applicant: Stephen James Russell et al.

Serial No.: 09/667,947

Filed : September 22, 2000

Page : 2 of 2

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 5/20/03

Monica McCormick Graham, Ph.D.

Attorney's Docket No.: 07039-298001

Reg. No. 42,600

Fish & Richardson P.C., P.A. 60 South Sixth Street Suite 3300

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

60142192.doc

Application No.: 09/667, 947

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

	3	. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
囚	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readar Employer (Sequence Listing" as required by 37 C.F.R. 1.821(e).
\Box	7.	Other: MAY 2 8 2003

TECH CENTER 1600/2900

Applicant Must Provide:

An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".

An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

SYAKSARORAKORAKAN ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form

ABOEWED) Application Serial Number: Source: Date Processed by STIC TECH CENTER (600/2000

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS. PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT. WITH A NOTICE TO COMPLY or
- TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT. WITH A NOTICE TO COMPLY

FOR CRE SUBMISSION QUESTIONS: PLEASE CONTACT MARK SPENCER 703-308-3212

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX: 703-308-4216 PATENITY 2:1 e-mail help: patin21help@uspto.gov.or phone 703 306-4119 (R. War) PATENTIN 3:0 e-mail help: patin3help@uspto.gov.or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS: http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette of CD-Rom should be aware that a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Ro Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses

- l: EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 222202
- 3. Hand Carry directly to:
 - U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1803, Crystal Plaza Two 2011 South Clark Place, Arlington, VA 22202
- Rederal Express, United Parcel Service, or other delivery service t : U.S. Patent and Trademark Office Box Sequence, Room 1803-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 09/667,947
ATTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
TWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3 Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length (1971)	Sequence(s)contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6Patentin 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <2.20>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to Include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
!	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
"bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
	n can only be used to represent a single-nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001

160C



DATE: 01/07/2003

TIME: 16:31:43

-cmpiv

in Nigadet

Input Set : A:\07039-298001.txt Output Set: N:\CRF4\01072003\I667947.raw 4 <110> APPLICANT: Russell, Stephen James Cattaneo, Roberto Peng, Kah-Whye Schneider, Urs Murphy, Anthea L. 10 <120> TITLE OF INVENTION: Therapeutic methods and compositions using viruses of the recombinant palamyxoviridae family 14 <130> FILE REFERENCE: 07039-298001 16 <140> CURRENT APPLICATION NUMBER: US 09/667,947 C--> 17 <141> CURRENT FILING DATE: 2002-12-18 19 <150> PRIOR APPLICATION NUMBER: US 60/155,873 20 <151> PRIOR FILING DATE: 1999-09-24 22 <160> NUMBER OF SEQ ID NOS: 49 24 <170> SOFTWARE: FastSEQ for Windows Version 4.0 26 <210> SEQ ID NO: 1 - invalid response see error summary sheet 27 <211> LENGTH: 4 28 <212> TYPE: PRT 29 <213> ORGANISM: (Fragment item 10 31 <400> SEQUENCE: 1 32 Ile Glu Gly Arg 33 1 The type of errors shown exist throughout 35 <210> SEQ ID NO: 2 the Sequence Listing. Please check subsequent 36 <211> LENGTH: 4 sequences for similar errors 37 <212> TYPE: PRT 38 <213> ORGANISM: (Fragment 40 <220> FEATURE: 41 <221> NAME/KEY: VARIANT 42 <222> LOCATION: 2 43 <223> OTHER INFORMATION: Xaa = Any 20 amino acids 45 <400> SEQUENCE: 2 W--> 46 Arg Xaa Lys Arg 47 1 49 <210> SEQ ID NO: 3 50 <211> LENGTH: 6 51 <212> TYPE: PRT 52 <213> ORGANISM: Fragment 54 <400> SEQUENCE: 3 55 Pro Leu Gly Leu Trp Ala 56 1 58 <210> SEQ ID NO: 4

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/667,947

61 <213> ORGANISM: Fragment

59 <211> LENGTH: 6 60 <212> TYPE: PRT

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/667,947

DATE: 01/07/2003 7667,947 TIME: 16:31:43

Input Set : A:\07039-298001.txt

```
63 <400> SEQUENCE: 4
64 Tyr Glu Val Asp Gly Trp
65 1
67 <210> SEQ ID NO: 5
68 <211> LENGTH: 7
69 <212> TYPE: PRT -
70 <213> ORGANISM: \Fragment
72 <400> SEQUENCE: 5
73 Val Asp Val Ala Asp Gly Trp
74 1
76 <210> SEQ ID NO: 6
77 <211> LENGTH: 7
78 <212> TYPE: PRT,
79 <213> ORGANISM: \Fragment
81 <400> SEQUENCE: 6
82 Val Asp Gln Not Asp Gly Trp
85 <210> SEQ ID NO: 7
86 <211> LENGTH: 6
87 <212> TYPE: PRT
88 <213> ORGANISM: Fragment
90 <400> SEQUENCE: 7
91 Leu Glu Val Asp Gly Trp
92 1
94 <210> SEQ ID NO: 8
95 <211> LENGTH: 6
96 <212> TYPE: PRT
97 <213> ORGANISM: Fragment
99 <400> SEQUENCE: 8
100 Val Gln Val Asp Gly Trp
        . 5
101 1
103 <210> SEQ ID NO: 9
104 <211> LENGTH: 7
105 <212> TYPE: PRT
106 <213> ORGANISM: (Fragment)
108 <400> SEQUENCE: 9
109 Val Asp Gln Val Asp Gly Trp
110 1
112 <210> SEQ ID NO: 10
113 <211> LENGTH: 4
114 <212> TYPE: PRT
115 <213> ORGANISM: Fragment
117 <400> SEQUENCE: 10 ----
118 Arg Gly Leu Thr
119 1
121 <210> SEQ ID NO: 11
122 <211> LENGTH: 17
123 <212> TYPE: PRT
124 <213> ORGANISM: Fragment
```

RAW SEQUENCE LISTINGPATENT APPLICATION: **US/09/667,947**DATE: 01/07/2003 TIME: 16:31:43

Input Set : A:\07039-298001.txt

```
126 <400> SEQUENCE: 11
 127 Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly
                                         10
 128 1
 129 Pro
 132 <210> SEQ ID NO: 12
 133 <211> LENGTH: 34
 134 <212> TYPE: PRT
135 <213> ORGANISM: Fragment /
 137 <400> SEQUENCE: 12
 138 Met Ser Pro Gln Arg Asp Arg Ile Asn Ala Phe Tyr Lys Asp Asn Pro
             5
                                        10
 140 His Pro Lys Gly Ser Arg Ile Val Ile Asn Arg Glu His Leu Met Ile
 141
 142 Asp Arg
 145 <210> SEQ ID NO: 13
 146 <211> LENGTH: 33
 147 <212> TYPE: PRT
 148 <213> ORGANISM: Fragment
 150 <400> SEOUENCE: 13
 151 Arg Gly Arg Cys Asn Lys Lys Gly Glu Gln Val Gly Met Ser Arg Pro
                     5
                                         10
 153 Gly Leu Lys Pro Asp Leu Thr Gly Thr Ser Lys Ser Tyr Val Arg Ser
 154
 155 Leu
 158 <210> SEQ ID NO: 14
 159 <211> LENGTH: 5
 160 <212> TYPE: PRT
 161 <213> ORGANISM: Fragment /
 163 <400> SEQUENCE: 14
 164 Arg Arg His Lys Arg
 165 1
 167 <210> SEQ ID NO: 15
 168 <211> LENGTH: 4
 169 <212> TYPE: PRT
 170 <213> ORGANISM: Fragment
 172 <400> SEQUENCE: 15
 173 Arg His Lys Arg
 174 1
 176 <210> SEQ ID NO: 16
 177 <211> LENGTH: 47
 178 <212> TYPE: DNA
 179 <213> ORGANISM: Artificial Sequence
 181 <220> FEATURE:
 182 <223> OTHER INFORMATION: Primer
 184 <400> SEQUENCE: 16
                                                                            47
 185 ttttcctttt gcggccgctt tcatcaacgc ttctgcaggg acccctc
 187 <210> SEQ ID NO: 17
 188 <211> LENGTH: 56
 189 <212> TYPE: DNA
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/667,947

DATE: 01/07/2003 TIME: 16:31:43

Input Set : A:\07039-298001.txt

```
190 <213> ORGANISM: Artificial Sequence
192 <220> FEATURE:
193 <223> OTHER INFORMATION: Primer
195 <400> SEQUENCE: 17
196 gtccatgcgg cccagccggc ccgattaaag agagaggcag aggacctgca ggtggg
                                                                           56
198 <210> SEQ ID NO: 18
199 <211> LENGTH: 18
200 <212> TYPE: PRT
201 <213> ORGANISM: Fragment
203 <400> SEQUENCE: 18
204 Val His Ala Ala Gln Pro Ala Arg Leu Lys Arg Glu Ala Glu Asp Leu
                    5
205 1
206 Gln Val
209 <210> SEQ ID NO: 19
210 <211> LENGTH: 50
211 <212> TYPE: DNA
212 <213> ORGANISM: Artificial Sequence
214 <220> FEATURE:
215 <223> OTHER INFORMATION: Primer
217 <400> SEQUENCE: 19
218 ttttcctttt gcggccgctt tcatcatcaa cgcttctgca gggacccctc
                                                                           50
220 <210> SEQ ID NO: 20
221 <211> LENGTH: 59
222 <212> TYPE: DNA
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: Primer
228 <400> SEQUENCE: 20
                                                                          59
229 gtccatgcqq cccaqccqqc cqgtgqaggc ggttcagagg cagaggacct gcaggtggg
231 <210> SEQ ID NO: 21
232 <211> LENGTH: 19
233 <212> TYPE: PRT
234 <213> ORGANISM: Fragment
236 <400> SEQUENCE: 21
237 Val His Ala Ala Gln Pro Ala Gly Gly Gly Ser Glu Ala Glu Asp
238 1
239 Leu Gln Val
242 <210> SEQ ID NO: 22
243 <211> LENGTH: 16
244 <212> TYPE: PRT
245 <213> ORGANISM: Fragment /
247 <400> SEQUENCE: 22
248 Arg Gly Arg Cys Asn Lys Lys Gly Glu Gln Gly Met Ser Arg Pro Gly
           5
                                        10
249 1
251 <210> SEQ ID NO: 23
252 <211> LENGTH: 9
253 <212> TYPE: PRT
254 <213> ORGANISM: Fragment
256 <400> SEQUENCE: 23
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/667,947

DATE: 01/07/2003 TIME: 16:31:43

Input Set : A:\07039-298001.txt

	Arg Gly Arg Cys Asn Lys Lys Gly Glu	
258	<210> SEQ ID NO: 24	
	<211> LENGTH: 26	
	<212> TYPE: DNA	
	<213> ORGANISM: Artificial Sequence	
	<220> FEATURE:	
266	<223> OTHER INFORMATION: Primer	
268	<400> SEQUENCE: 24	
	aaaactgcag actcaaaggt caatgc	26
	<210> SEQ ID NO: 25	
272	<211> LENGTH: 30	
273	<212> TYPE: DNA	
274	<213> ORGANISM: Artificial Sequence	
	<220> FEATURE:	
	<223> OTHER INFORMATION: Primer	
	<400> SEQUENCE: 25	20
	cccttaatta atatacagat ctcaacggat	30
	<210> SEQ ID NO: 26	
	<211> LENGTH: 31	
	<212> TYPE: DNA	
	<213> ORGANISM: Artificial Sequence <220> FEATURE:	
	<pre><220> FEATORE: <223> OTHER INFORMATION: Primer</pre>	
	<400> SEQUENCE: 26	
	ccatcgataa tggccttcta caaagataac c	31
	<210> SEQ ID NO: 27	
	<211> LENGTH: 33	
	<212> TYPE: DNA	
296	<213> ORGANISM: Artificial Sequence	
298	<220> FEATURE:	
299	<223> OTHER INFORMATION: Primer	
	<400> SEQUENCE: 27	
	ccatcgataa tgagccatcc caagggaagt agg	33
	<210> SEQ ID NO: 28	
	<211> LENGTH: 33	
	<212> TYPE: DNA	
	<213> ORGANISM: Artificial Sequence	
	<220> FEATURE:	
	<223> OTHER INFORMATION: Primer <400> SEQUENCE: 28	
	ccatcgataa tgaacagaga acatcttatg att	33
	<210> SEQ ID NO: 29	
	<211> LENGTH: 29	
	<212> TYPE: DNA	
	<213> ORGANISM: Artificial Sequence	
	<220> FEATURE:	
	<223> OTHER INFORMATION: Primer	
_	<400> SEQUENCE: 29	

RAW SEQUENCE LISTING ERROR SUMMARY

PATENT APPLICATION: US/09/667,947

DATE: 01/07/2003 TIME: 16:31:44

Input Set : A:\07039-298001.txt

Output Set: N:\CRF4\01072003\I667947.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 2

Seq#:35; Xaa Pos. 5,6,7

Seq#:36; N Pos. 1,2,3,4,5,6,7,8,9,10,11,12,15,16,17,20

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/667,947

DATE: 01/07/2003 TIME: 16:31:44

Input Set : A:\07039-298001.txt

Output Set: N:\CRF4\01072003\I667947.raw

L:17 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:46 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0 L:396 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:35 L:400 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:35 L:401 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35 after pos.:0 L:418 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:422 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:426 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:430 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:434 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:438 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:442 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:446 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:450 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:454 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:458 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:462 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:466 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:36 L:467 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36 after pos.:0